Morgan Stanley
NPCE icon

Morgan Stanley’s Neuropace NPCE Stock Holding History

Morgan Stanley’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.2M Buy
2,654,391
+87,552
+3% +$1.41M ﹤0.01% 2414
2026
Q1 		$33.8M Buy
2,566,839
+19,055
+0.7% +$286K ﹤0.01% 2488
2025
Q4 		$39.3M Buy
2,547,784
+1,576
+0.1% +$21.1K ﹤0.01% 2319
2025
Q3 		$26.3M Sell
2,546,208
-38,865
-2% -$366K ﹤0.01% 2617
2025
Q2 		$28.8M Buy
2,585,073
+54,453
+2% +$681K ﹤0.01% 2451
2025
Q1 		$31.1M Buy
2,530,620
+38,790
+2% +$486K ﹤0.01% 2252
2024
Q4 		$27.9M Sell
2,491,830
-2,511
-0.1% -$21.8K ﹤0.01% 2418
2024
Q3 		$17.4M Buy
2,494,341
+23,199
+0.9% +$170K ﹤0.01% 2930
2024
Q2 		$18.7M Sell
2,471,142
-12,841
-0.5% -$130K ﹤0.01% 2740
2024
Q1 		$32.8M Buy
2,483,983
+23,267
+0.9% +$332K ﹤0.01% 2165
2023
Q4 		$25.4M Buy
2,460,716
+61,000
+3% +$486K ﹤0.01% 2435
2023
Q3 		$23.3M Buy
2,399,716
+40,850
+2% +$239K ﹤0.01% 2290
2023
Q2 		$10.6M Buy
2,358,866
+100,850
+4% +$456K ﹤0.01% 3100
2023
Q1 		$10.5M Buy
2,258,016
+69,423
+3% +$266K ﹤0.01% 3100
2022
Q4 		$3.26M Buy
2,188,593
+64,990
+3% +$144K ﹤0.01% 4120
2022
Q3 		$7.96M Buy
2,123,603
+138,414
+7% +$667K ﹤0.01% 3199
2022
Q2 		$9.83M Buy
1,985,189
+949,405
+92% +$6.27M ﹤0.01% 3080
2022
Q1 		$8.5M Buy
1,035,784
+769,556
+289% +$6.64M ﹤0.01% 3096
2021
Q4 		$2.68M Buy
266,228
+258,570
+3,376% +$3.36M ﹤0.01% 4337
2021
Q3 		$121K Buy
7,658
+66
+0.9% +$1.39K ﹤0.01% 6265
2021
Q2 		$181K Buy
+7,592
New +$176K ﹤0.01% 6066

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley's NPCE Position: Q2 2026 in Review

Morgan Stanley increased its Neuropace (NPCE) stake by 3.4% in Q2 2026, buying an estimated $1.41M and bringing the position to 2,654,391 shares worth $42.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2414.

Morgan Stanley first reported a position in NPCE in Q2 2021 and has held it in 21 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Morgan Stanley held 2,654,391 shares of Neuropace worth $42.2M as of Q2 2026.
  • Morgan Stanley bought 87,552 Neuropace shares in Q2 2026, an estimated $1.41M.
  • Neuropace made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2414 holding.
  • Morgan Stanley first reported a position in Neuropace in Q2 2021 and has held it in 21 quarters since.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.